WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011139391) GROWTH HORMONE RECEPTOR DEFICIENCY CAUSES A MAJOR REDUCTION IN PRO-AGING SIGNALING, CANCER AND DIABETES IN HUMANS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/139391    International Application No.:    PCT/US2011/022052
Publication Date: 10.11.2011 International Filing Date: 21.01.2011
IPC:
A61K 39/395 (2006.01), A61K 38/22 (2006.01), A61K 38/18 (2006.01), A61P 35/00 (2006.01), A61P 3/10 (2006.01), A61P 9/00 (2006.01)
Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; USC Stevens 3740 McClintock Avenue Hughes Center, Suite EEB131 Los Angeles, CA 90089-2561 (US) (For All Designated States Except US).
LONGO, Valter, D. [IT/US]; (US) (For US Only).
GUEVARA, Jaime [CL/US]; (For US Only)
Inventors: LONGO, Valter, D.; (US).
GUEVARA, Jaime;
Agent: PROSCIA, James, W.; Brooks Kushman P.C. 1000 Town Center Twenty-Second Floor Southfield, MI 48075 (US)
Priority Data:
61/328,812 28.04.2010 US
Title (EN) GROWTH HORMONE RECEPTOR DEFICIENCY CAUSES A MAJOR REDUCTION IN PRO-AGING SIGNALING, CANCER AND DIABETES IN HUMANS
(FR) FORTE DIMINUTION DE LA SIGNALISATION PRO-VIEILLISSEMENT, DU CANCER ET DU DIABÈTE CHEZ L'ÊTRE HUMAIN SOUS L'EFFET D'UN DÉFICIT EN RÉCEPTEURS DE L'HORMONE DE CROISSANCE
Abstract: front page image
(EN)A method for alleviating a symptom of chemotherapy in a subject comprises identifying a subject undergoing chemotherapy and then administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject. Typically, the levels of IGF-1 and/or GH in the subject are monitored as well as chemotherapy related symptoms. A method of alleviating oxidative damage, cellular damage including mutations, and insulin resistance in a subject is also provided.
(FR)Une méthode permettant d'atténuer les symptômes d'une chimiothérapie chez un sujet comprend les étapes consistant à identifier un sujet faisant l'objet d'une chimiothérapie, puis à lui administrer une quantité thérapeutiquement efficace d'une composition inhibitrice de l'axe GH/IGF-1. De façon générale, les niveaux d'IGF-1 et/ou de GH chez le sujet font l'objet d'un suivi, de même que les symptômes associés à la chimiothérapie. L'invention concerne également une méthode d'inhibition du stress oxydatif, des lésions cellulaires, notamment les mutations, et de la résistance à l'insuline chez un sujet.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)